ProKidney

Yahoo Finance • 3 months ago

ProKidney Reports Business Updates and Second Quarter 2024 Financial Results

ProKidney Reported interim REGEN-007 data that demonstrate rilparencel’s potential to preserve kidney function in patients with diabetes and advanced CKD Restarted manufacturing and resumed PROACT 1 and PROACT 2 Phase 3 trials Closed $14... Full story

Yahoo Finance • 6 months ago

ProKidney Reports Business Updates and First Quarter 2024 Financial Results

ProKidney Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD with Dr. A... Full story

Yahoo Finance • 10 months ago

Chamath Palihapitiya Stocks: 12 Stocks Pumped in the Last 10 Years

In this article, we discuss Chamath Palihapitiya and the 12 stocks he pumped in the last 10 years. If you want to read about some more Chamath Palihapitiya stocks, go directly to Chamath Palihapitiya Stocks: 5 Stocks Pumped in the Last 10... Full story

Yahoo Finance • 11 months ago

ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer

WINSTON-SALEM, N.C., Nov. 30, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the appointment of... Full story

Yahoo Finance • 12 months ago

ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference

WINSTON-SALEM, N.C, Nov. 21, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients living wit... Full story

Yahoo Finance • 12 months ago

ProKidney Reports Third Quarter Financial Results

WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results f... Full story

Yahoo Finance • 12 months ago

ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients Focusing Phase 3 development program on patients with Stage 3b and 4 diabetic CKD a... Full story

Yahoo Finance • last year

ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference

WINSTON-SALEM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients sufferin... Full story

Yahoo Finance • last year

ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization

- Brings more than 20 years of academic and industry experience with extensive expertise in kidney disease - WINSTON-SALEM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading... Full story

Yahoo Finance • last year

ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC

WINSTON-SALEM, N.C., June 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering... Full story

Yahoo Finance • 2 years ago

ProKidney to Present at the BofA Securities Health Care Conference 2023

WINSTON-SALEM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram... Full story

Yahoo Finance • 2 years ago

ProKidney to Participate in TD Cowen’s 43rd Annual Health Care Conference

WINSTON-SALEM, N.C., March 03, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertr... Full story

Yahoo Finance • 2 years ago

ProKidney’s stock jumps 29%

MARKET PULSE Shares of ProKidney Corp. (PROK) rallied about 29% in premarket trading on Wednesday, the day after the company said preliminary data from a Phase 2 study found that the company’s investigational renal autologous cell therapy... Full story

Yahoo Finance • 2 years ago

ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease

- Article published online in the Journal of Blood Purification; to be included in future print edition - WINSTON-SALEM, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage... Full story